Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
- PMID: 17159987
- DOI: 10.1038/nm1517
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Abstract
Cancer immunoresistance and immune escape may play important roles in tumor progression and pose obstacles for immunotherapy. Expression of the immunosuppressive protein B7 homolog 1 (B7-H1), also known as programmed death ligand-1 (PD-L1), is increased in many pathological conditions, including cancer. Here we show that expression of the gene encoding B7-H1 increases post transcriptionally in human glioma after loss of phosphatase and tensin homolog (PTEN) and activation of the phosphatidylinositol-3-OH kinase (PI(3)K) pathway. Tumor specimens from individuals with glioblastoma multiforme (GBM) had levels of B7-H1 protein that correlated with PTEN loss, and tumor-specific T cells lysed human glioma targets expressing wild-type PTEN more effectively than those expressing mutant PTEN. These data identify a previously unrecognized mechanism linking loss of the tumor suppressor PTEN with immunoresistance, mediated in part by B7-H1.
Similar articles
-
PTEN/PI3K/mTOR/B7-H1 signaling pathway regulates cell progression and immuno-resistance in pancreatic cancer.Hepatogastroenterology. 2013 Oct;60(127):1766-72. Hepatogastroenterology. 2013. PMID: 24624456
-
The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo.Cancer Res. 2006 Dec 1;66(23):11331-40. doi: 10.1158/0008-5472.CAN-06-1540. Cancer Res. 2006. PMID: 17145879
-
Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion.Neuroreport. 2009 Dec 9;20(18):1597-602. doi: 10.1097/WNR.0b013e32833188f7. Neuroreport. 2009. PMID: 19875977 Free PMC article.
-
Pten signaling in gliomas.Neuro Oncol. 2002 Jul;4(3):196-211. Neuro Oncol. 2002. PMID: 12084351 Free PMC article. Review.
-
Dissecting the signaling pathways that mediate cancer in PTEN and LKB1 double-knockout mice.Sci Signal. 2015 Sep 1;8(392):pe1. doi: 10.1126/scisignal.aac8321. Sci Signal. 2015. PMID: 26329580 Review.
Cited by
-
Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma.Cancer Drug Resist. 2024 Oct 31;7:42. doi: 10.20517/cdr.2024.54. eCollection 2024. Cancer Drug Resist. 2024. PMID: 39534873 Free PMC article. Review.
-
The two-sided battlefield of tumour-associated macrophages in glioblastoma: unravelling their therapeutic potential.Discov Oncol. 2024 Oct 25;15(1):590. doi: 10.1007/s12672-024-01464-5. Discov Oncol. 2024. PMID: 39453528 Free PMC article. Review.
-
Immunoediting Dynamics in Glioblastoma: Implications for Immunotherapy Approaches.Cancer Control. 2024 Jan-Dec;31:10732748241290067. doi: 10.1177/10732748241290067. Cancer Control. 2024. PMID: 39353594 Free PMC article. Review.
-
Dual targeting macrophages and microglia is a therapeutic vulnerability in models of PTEN-deficient glioblastoma.J Clin Invest. 2024 Oct 1;134(22):e178628. doi: 10.1172/JCI178628. J Clin Invest. 2024. PMID: 39352749 Free PMC article.
-
Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape.Front Immunol. 2024 Sep 13;15:1424396. doi: 10.3389/fimmu.2024.1424396. eCollection 2024. Front Immunol. 2024. PMID: 39346924 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous